glp-1 parkinson's disease lancet A New Treatment Strategy for through the Gut–Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway Exenatide once weekly versus placebo

It is intended as an evidence-based reference for patients, dietitians, pharmacists and prescribers seeking clarity on how to maintain micronutrient adequacy during GLP-1 therapy

The mechanisms underlying dizziness with weight loss injections are multifactorial and relate to both the pharmacological actions of these medications and secondary physiological changes associated with weight loss and reduced caloric intake

GLP-1 medications also decrease pancreatic enzyme secretion reducing enzymes like trypsin and lipase by over 40% further impairing fat digestion

These effects are often the result of slowed gastric emptyingthe very mechanism that increases satiety and reduces food intake

Ambos medicamentos son comercializados por el gigante farmacutico dans Novo Nordisk